Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia

Melissa B. Pappalardi, Kathryn Keenan, Mark Cockerill, Wendy A. Kellner, Alexandra Stowell, Christian Sherk, Kristen Wong, Sarath Pathuri, Jacques Briand, Michael Steidel, P Chapman, Arthur Groy, Ashley K. Wiseman, Charles F. McHugh, Nino Campobasso, Alan P. Graves, Emma Fairweather, Thilo Werner, Ali Raoof, Roger J. Butlin, Lourdes Rueda, J.R. Horton, David T. Fosbenner, Cunyu Zhang, Jessica L. Handler, Morris Muliaditan, Makda Mebrahtu, Jon‐Paul Jaworski, Dean E. McNulty, Charlotte Burt, H. Christian Eberl, Amy Taylor, Thau Ho, Susan Merrihew, Shawn W. Foley, Anna Rutkowska, Mei Li, Stuart P. Romeril, Kristin Goldberg, Xing Zhang, Christopher S. Kershaw, Marcus Bantscheff, Anthony J. Jurewicz, Elisabeth A. Minthorn, Paola Grandi, Mehul Patel, Andrew B. Benowitz, Helai P. Mohammad, Aidan G. Gilmartin, Rab K. Prinjha, Donald Ogilvie, Christopher Carpenter, Dirk A. Heerding, Stephen B. Baylin, Peter A. Jones, Xiaodong Cheng, Bryan W. King, Juan I. Luengo, Allan M. Jordan, Ian D. Waddell, Ryan G. Kruger, Michael T. McCabe